A Phase III Study of Adjuvant Ganglioside Vaccination GM2-KLH/QS-21 Therapy vs. High-Dose Interferon Alfa-2b (IntronA) for High-Risk Melanoma (T4 > 4 mm Primary or Regional Lymph Node Metastasis)
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study was to assess at biomarkers in patients with high-risk melanoma receiving high-dose interferon therapy.
Description
The purpose of this study was to assess at biomarkers in patients with high-risk melanoma receiving high-dose interferon therapy.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
melanoma
-
Age: - 100 Years
-
Gender: All
Updated on
20 Nov 2022.
Study ID: 1609341481